Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 |
| clinicaltrials |
| NCT03786003 | ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) | recruiting | N/A | 1,086 | Fudan UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05837052 | A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | recruiting | Phase 2 | 49 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | recruiting | Phase 2 | 41 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05934032 | National Network Genomic Medicine Lung Cancer, Germany(nNGM) | recruiting | — | 30,000 | Prof. Dr. Juergen WolfOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05913089 | A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | recruiting | Phase 2 | 58 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05802654 | Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer(USBRT-1) | not yet recruiting | N/A | 100 | Peking University Third HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05432739 | Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study | recruiting | — | 500 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05904015 | The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05857800 | Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment(NAT-LungMate) | recruiting | — | 2,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05891080 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | not yet recruiting | Phase 2 | 124 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05663242 | The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action | recruiting | Phase 4 | 300 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05881057 | Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer | not yet recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05778708 | Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients | recruiting | N/A | 318 | The University of Hong KongOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05851755 | Italian Lung Cancer Observational Study(LUCENT) | enrolling by invitation | — | 1,000 | The Mediterranean Institute for Transplantation and Advanced Specialized TherapiesOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05822284 | ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy | not yet recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | recruiting | Phase 1 / Phase 2 | 140 | Shanghai Chest HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05811169 | Quest for Tumour Evolution of Non-small Cell Lung Cancer | active not recruiting | — | 60 | The University of Hong KongOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT01994057 | A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment | recruiting | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800340 | Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05797493 | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer(PICASSO) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05784974 | Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer | not yet recruiting | Phase 2 | 37 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05784142 | Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)(CHIC) | active not recruiting | Phase 2 | 55 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01763125 | Establishment of a Tumor Bank for Blood Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 4 | Mar 23, 2023 | clinicaltrials |
| NCT01789229 | Establishment of a Tumor Bank for Tissue Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 3 | Mar 23, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05778253 | The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC | recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05286957 | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC(Seagull) | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours(CAMP1) | not yet recruiting | Phase 1 | 50 | Mabpro, a.s.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05354596 | A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).(STRICTSTARLUNG) | recruiting | N/A | 138 | Rigshospitalet, DenmarkOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05736029 | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics(PROPHETIC) | recruiting | — | 350 | OncoHost Ltd.INDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction(FASTIMMUNE) | not yet recruiting | Phase 2 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05698264 | A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC | not yet recruiting | N/A | 50 | Nir PeledOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT04677205 | Molecular Signature From Tumor to Lymph Nodes(N2-3S) | recruiting | — | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05596578 | Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion | recruiting | — | 958 | Luzerner KantonsspitalOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05676788 | HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections(HYPER-Seg) | not yet recruiting | N/A | 50 | LungenClinic GrosshansdorfOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05537922 | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | recruiting | — | 2,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 4 | Jan 6, 2023 | clinicaltrials |
| NCT05636605 | Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy | recruiting | — | 200 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT04720339 | Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. | recruiting | N/A | 250 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05621902 | Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer(LUCA-S) | not yet recruiting | N/A | 398 | Mats LambeOTHER | 0 | Nov 18, 2022 | clinicaltrials |
| NCT04451473 | Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery | recruiting | N/A | 350 | The Second Hospital of Shandong UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2023source: clinicaltrials